Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis

Trial Profile

A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Sep 2019 Results published in the journal of Cystic Fibrosis
    • 10 Sep 2019 Results published in the Santhera Pharmaceuticals Media Release
    • 24 Oct 2018 Status changed from recruiting to completed, according to a Santhera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top